1. Home
  2. AUPH vs ERII Comparison

AUPH vs ERII Comparison

Compare AUPH & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • ERII
  • Stock Information
  • Founded
  • AUPH 1993
  • ERII 1992
  • Country
  • AUPH Canada
  • ERII United States
  • Employees
  • AUPH N/A
  • ERII N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • ERII Industrial Machinery/Components
  • Sector
  • AUPH Health Care
  • ERII Technology
  • Exchange
  • AUPH Nasdaq
  • ERII Nasdaq
  • Market Cap
  • AUPH 1.1B
  • ERII 675.8M
  • IPO Year
  • AUPH 1999
  • ERII 2008
  • Fundamental
  • Price
  • AUPH $8.77
  • ERII $12.93
  • Analyst Decision
  • AUPH Strong Buy
  • ERII Strong Buy
  • Analyst Count
  • AUPH 2
  • ERII 4
  • Target Price
  • AUPH $11.50
  • ERII $18.88
  • AVG Volume (30 Days)
  • AUPH 1.4M
  • ERII 413.9K
  • Earning Date
  • AUPH 07-31-2025
  • ERII 07-30-2025
  • Dividend Yield
  • AUPH N/A
  • ERII N/A
  • EPS Growth
  • AUPH N/A
  • ERII 9.93
  • EPS
  • AUPH 0.27
  • ERII 0.37
  • Revenue
  • AUPH $247,295,000.00
  • ERII $140,923,000.00
  • Revenue This Year
  • AUPH $12.15
  • ERII $4.82
  • Revenue Next Year
  • AUPH $18.31
  • ERII $12.97
  • P/E Ratio
  • AUPH $31.76
  • ERII $34.89
  • Revenue Growth
  • AUPH 29.20
  • ERII 10.93
  • 52 Week Low
  • AUPH $5.20
  • ERII $10.86
  • 52 Week High
  • AUPH $10.67
  • ERII $20.27
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 66.00
  • ERII 49.69
  • Support Level
  • AUPH $7.71
  • ERII $11.88
  • Resistance Level
  • AUPH $8.29
  • ERII $12.73
  • Average True Range (ATR)
  • AUPH 0.25
  • ERII 0.28
  • MACD
  • AUPH 0.03
  • ERII 0.09
  • Stochastic Oscillator
  • AUPH 84.40
  • ERII 64.04

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About ERII Energy Recovery Inc.

Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the global reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.

Share on Social Networks: